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Abstract
Background: This study investigated mechanisms of altered fibroblast collagen production
induced by polyunsaturated fatty acids. 3T3-Swiss fibroblasts were grown in medium containing
either eicosapentaenoic or arachidonic acid. The effects of nuclear factor-kappaB activation by
lipopolysaccharide on inducible nitric oxide synthase, nitric oxide, prostaglandin E2, collagen
production, and in-vitro wound healing were studied.
Results: Eicosapentaenoic acid treated cells produced less prostaglandin E2 but had increased
inducible nitric oxide synthase expression, nitric oxide production, collagen formation, and
recoverage area during in-vitro wound healing than cells treated with arachidonic acid. Activation of
nuclear factor-kappaB with lipopolysaccharide increased inducible nitric oxide synthase expression,
the production of nitric oxide, prostaglandin E2, collagen, and the in-vitro wound recoverage area.
The nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester, decreased
lipopolysaccharide-induced nitric oxide, but the amount of nitric oxide was greater in
eicosapentaenoic acid treated cells. NG-nitro-L-arginine methyl ester plus lipopolysaccharide
treatment increased collagen production and cellular recoverage area while treatment with NGnitro-L-arginine methyl ester alone decreased it in wounded fibroblasts.
Conclusion: The activation of the NF-κB pathway and PGE2 can be linked by the cross-talk of
iNOS and NO in the PUFA altered fibroblast collagen production and wound healing. Additional
studies are needed to determine how polyunsaturated fatty acids can be used as adjuvants in
combination with other treatments (i.e, drugs) to design therapies to either enhance healthy
collagen production or inhibit production and reduce fibrosis.

Background
The purpose of this research was to test the hypothesis
that polyunsaturated fatty acids can alter collagen formation during in-vitro healing by changing iNOS expression
and NO production, which have cross-interaction with
the nuclear transcription factor kappaB (NF-κB) pathway
and PGE2. The control of collagen formation for optimal
healing in tissues and organs is essential for numerous

diseases [1-3]. The healing of skin and connective tissues
such as ligaments require enhanced and effective production of healthy collagen for strength and to shorten the
recovery time, but without scarring. However, collagen
formation in injured vital organs needs to be minimized
to prevent fibrosis and subsequent loss of organ function.
Both enhanced and reduced collagen formation likely
have common regulatory mechanisms that remain to be
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Our previous studies showed that polyunsaturated fatty
acids (PUFA) alter collagen production in avian chondrocytes [8], porcine medial collateral ligament fibroblasts
[9], and murine 3T3-Swiss fibroblasts [5]. Eicosapentaenoic acid (EPA, 20:5 n-3) treated porcine medial collateral
ligament fibroblasts produced more collagen than those
treated with arachidonic acid (AA, 20:4 n-6) [9]. In
murine 3T3-Swiss fibroblasts, we have observed that collagen production could be regulated by exposure to different n-6: n-3 PUFA ratios and these effects were mediated,
in part, by PGE2 and changes in the signaling via the different PGE receptor subtypes [5].
Since many collagen formation associated genes have promoter or enhancer elements for NF-κB [10], we studied
the different response of NF-κB related genes to EPA and
AA treatments in 3T3-Swiss fibroblasts by a gene profiling
system [11]. Treatments with lipopolysaccharide (LPS),
an NF-κB inducer, stimulated increased expression of several genes in the NF-κB pathway that are linked collagen
production (i.e, interleukin-6 and inducible nitric oxide
synthase).
The activated NF-κB dimer binds to the 5'-flanking region
of the iNOS promoter and induces iNOS formation [12].
Inducible nitric oxide synthase (iNOS) and nitric oxide
(NO) have an important role in collagen formation during wound healing [13,14]. Inhibition of NO synthase
significantly decreased collagen synthesis in wound
fibroblasts [13]. Dermal fibroblasts from iNOS-knock out
murine fibroblasts proliferated more slowly and synthesized less collagen, and NO donors restored the collagen
synthesis to normal level [15]. Another study implicated a
role for NO in PGE2 formation and collagen deposition in
rats [16]. Therefore, endogenous iNOS and NO may link
the NF-κB pathway to PGE2 and regulate collagen formation during wound healing.

Results
Real-time RT-PCR for iNOS mRNA
The transcriptional level of iNOS mRNA was determined
by the real-time RT-PCR (Figure 1). The expression of
iNOS mRNA can be altered by stimulation of the NF-κB
pathway. Incubation with the NF-κB pathway inducer,
lipopolysaccharide (LPS, 10 µg/ml), significantly (P <
0.01) increased the expression of iNOS mRNA in both
arachidonic acid (AA, 20:4 n-6) and eicosapentanoic acid
(EPA, 20:5 n-3) treated normal or wounded 3T3-Swiss
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The percentage of iNOS to
β- ACTIN expression (%)

elucidated. Multiple cellular and extracellular factors can
influence collagen formation, such as nitric oxide [4],
PGE2 [5], as well as growth factors [6] and matrix metalloproteinases [7]. Therefore, potential therapies to control
healing may require an approach targeting multiple molecules or mechanisms.
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Figure 1 RT-PCR
Real-time
fibroblasts
n = 3, ± for
SD)iNOS mRNA expression in 3T3-Swiss
Real-time RT-PCR for iNOS mRNA expression in
3T3-Swiss fibroblasts n = 3, ± SD). The expression of
iNOS mRNA can be altered by stimulation of the NF-κB
pathway or inhibition of nitric oxide synthase in 3T3-Swiss
fibroblasts. EPA treated fibroblasts were more sensitive to
the changes of NF-κB pathway than AA treated cells. Cells
were incubated for 48 hr with bovine serum albumin alone as
control or bovine serum albumin-soap loaded fatty acids (25
µM). Medium was then replaced with fresh fatty acid
enriched medium containing lipopolysaccharide (LPS, 10 µg/
ml) with or without NG-nitro-L-arginine methyl ester (LNAME, 10-7 M) for another 24 hr. The wound was created
after initial 48 hr treatments in duplicate set of plate with or
without LPS. Cells were harvested at 24 hr post wounding
and real-time RT-PCR was performed. The results were presented as the percentage of iNOS to β-actin mRNA expression. Bars with different letters are significantly different (P <
0.05). EPA, eicosapentaenoic acid; AA, arachidonic acid; LPS,
lipopolysaccharide; L-NAME, NG-nitro-L-arginine methyl
ester.

fibroblasts. However, the EPA-treated fibroblasts were
more responsive to induction of the NF-κB pathway than
AA-treated cells. Activation of the NF-κB pathway in EPAtreated cells with LPS resulted in significantly increased (P
< 0.001) transcription of iNOS mRNA compared to AAtreated cells. The addition of the nitric oxide synthase
inhibitor, NG-nitro-L-arginine methyl ester (L-NAME, 107 M) resulted in a significant increase (P < 0.05) in the
transcription of iNOS mRNA only in EPA-treated fibroblasts with LPS stimulation.
Quantification of nitrite
A stable end product of NO synthesis, nitrite, was measured to determine the NO concentration (Figure 2). The
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Activation of NF-κB pathway by LPS in 3T3-Swiss fibroblasts significantly increased (p < 0.05) the production of
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production of nitrite can be changed by altering the activity of the NF-κB pathway and nitric oxide synthase. EPAtreated normal fibroblasts without LPS stimulation produced more nitrite than control or AA-treated fibroblasts.
However, when stimulated by LPS, EPA-treated normal
fibroblasts produced significantly (P < 0.05) less nitrite
than control or AA-treated cells. Treatment with L-NAME
significantly reduced LPS-induced nitrite production, and
EPA-treated cells produced more nitrite than AA-treated
cells. Wounded and LPS stimulated cells decreased nitrite
production for all treatments compared to LPS alone, but
EPA-treated fibroblasts produced less nitrite than AAtreated or control cells.
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NO production in 3T3-Swiss fibroblasts (n = 3, ± SD).
Cells were incubated for 48 hr with bovine serum albumin
alone as control or bovine serum albumin-soap loaded fatty
acids (25 µM). Medium was then replaced with fresh fatty
acid enriched medium containing lipopolysaccharide (LPS, 10
µg/ml) with or without NG-nitro-L-arginine methyl ester (LNAME, 10-7 M) for another 24 hr. The wound was created
after initial 48 hr treatments in a duplicate set of plate with
LPS treatments. Culture supernatants (100 µl) were collected at 24 hr post wounding and quantification of nitrite
was performed. The results were presented as the nitrite
concentration (µM). Bars with different letters are significantly different (P < 0.05). EPA, eicosapentaenoic acid; AA,
arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitroL-arginine methyl ester.
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PGE2 production in 3T3-Swiss fibroblasts n = 3, ± SD).
The addition incubation of nitric oxide synthase inhibitor
decreased the LPS induced PGE2 production in 3T3-Swiss
fibroblasts. Cells were incubated for 48 hr with bovine serum
albumin alone as control or bovine serum albumin-soap
loaded fatty acids (25 µM). Medium was then replaced with
fresh fatty acid enriched medium containing lipopolysaccharide (LPS, 10 µg/ml) with or without NG-nitro-L-arginine
methyl ester (L-NAME, 10-7 M) for another 24 hr. The
wound was created after initial 48 hr treatments in duplicate
set of plate with or without LPS. Culture supernatants were
collected at 24 hr post wounding and the quantification of
PGE2performed. The results were presented as the PGE2
concentration (pg/ml). Bars with different letters are significantly different (P < 0.05). EPA, eicosapentaenoic acid; AA,
arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitroL-arginine methyl ester.

PGE2 over control levels for all groups (Figure 3). Both
basal and LPS stimulated amounts of PGE2 were lowest in
EPA-treated fibroblasts compared to the control and AAtreated cells. The addition of the nitric oxide synthase
inhibitor, L-NAME, to LPS stimulated fibroblasts
decreased PGE2 production to basal levels for all groups.
Wounding of LPS stimulated cells did not significantly
change the amount of PGE2 produced by cells when compared with those stimulated by LPS alone.
Collagen formation
Wounded fibroblasts without any PFA treatment
increased both collagen production (CP) and collagen as
a percentage of total proteins (C-PTP) compared to
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Table 1: Primers for iNOS and β-actin. Primers for iNOS and β-actin were designed by Primer Express®2.0 (Applied Biosystems).
iNOS, inducible nitric oxide synthase.

Gene

Genebank accession #

Start positions

Primer sequences (5' ? 3')

Amplicon length (bp)

iNOS

U43428
X03672

AGGGAATCTTGGAGCGAGTTGT
AGCCTCTTGTCTTTGACCCAGT
TGGAATCCTGTGGCATCCATGA
AGCACTGTGTTGGCATAGAGGT

103

β-actin

2407
2509
886
976

91

Table 2: Collagen formation in 3T3-Swiss fibroblasts (n = 3, ± SD). Cells were incubated for 48 hr with bovine serum albumin alone as
control or bovine serum albumin-soap loaded fatty acids (25 µM). The wound was then created and the medium was then replaced
with fresh fatty acid enriched medium containing 50 µM ascorbic acid and 5 µCi of 3H-proline with or without lipopolysaccharide (LPS,
10 µg/ml) and NG-nitro-L-arginine methyl ester (L-NAME, 100 nM). A duplicate set of plates was made without wounding. Cells were
harvested at 24 hr post wounding and assayed for collagen, total protein and DNA. The amount of collagen is expressed as DPM from
3H-proline per µg of DNA. Mean values within rows having different superscripts are significantly different (P < 0.05) by 1-way ANOVA
and Tukey test. EPA, eicosapentaenoic acid; AA, arachidonic acid; LPS, lipopolysaccharide; L-NAME, NG-nitro-L-arginine methyl
ester.

Treatments
Control
Wound
LPS
L-NAME
LPS + Wound
LPS + L-NAME
LPS + L-NAME + EPA
LPS + L-NAME + AA

Collagen production (CP) (DPM/µg DNA amount)

Collagen as a percentage of total protein (C-PTP) (%)

2419.6 ± 318.1a
3044.8 ± 269.2b
3953.3 ± 57.3c
1225.6 ± 270.7d
2650.3 ± 146.9ab
5393.7 ± 583.4e
6580.2 ± 418.3e
3511.3 ± 561.4c

18.7 ± 1.6a
21.8 ± 1.5b
26.5 ± 0.8c
11.4 ± 2.7d
19.0 ± 1.8ab
37.5 ± 3.3e
42.4 ± 5.6e
26.7 ± 4.0c

control (non-wounded, no PFA treatment) fibroblasts
(Table 2). However, wounded fibroblasts treated with LPS
produced less collagen and C-PTP than the control cells
with LPS stimulation. Treatment with L-NAME alone
decreased collagen production in control fibroblasts,
while the additional of L-NAME plus LPS produced more
collagen and had more collagen as a percentage of total
protein in both control and wounded fibroblasts. The
combination treatments of EPA, L-NAME and LPS produced higher CP and C-PTP than treatments of AA, LNAME and LPS in normal fibroblasts.
In-vitro wounding assay
The cellular recoverage area in wounded fibroblasts
changed by the treatments of LPS, nitric oxide synthase
inhibitor, cyclooxygenase (COX) inhibitor, and PFA (Figure 4). After 24 hr post wounding, LPS activation of the
NF-κB pathway increased the percentage of cellular recoverage area compared to the control. The treatment of LNAME alone decreased the percentage of cellular recoverage area in all groups while the treatment of L-NAME plus
LPS increased the cellular recoverage area compared to
LPS treatment alone. Administration of indomethacin, a

cyclooxygenase inhibitor, increased the cellular recoverage area in LPS stimulated fibroblasts. The treatments of
EPA and AA alone both increased the recoverage area
compared to the control. EPA-treated fibroblasts with LPS
had a higher the percentage of cellular recoverage area
than the AA plus LPS treated cells, with or without other
treatments.

Discussion
Polyunsaturated fatty acids affect the formation of numerous mediators of inflammation, such as eicosanoids and
cytokines [9]. Thus, dietary fatty acids, those mobilized
from cellular phospholipids or triacylglycerols stored in
adipose tissue, and topical applications [18] can all potentially influence wound healing. A limited number of studies have examined the effects of dietary or topical
applications of PUFA on wound healing. A cutaneous
wound healing study found that rats fed a diet enriched in
n-3 fatty acids produced wounds that were weaker in tensile strength compared to those from rats fed a diet containing n-6 fatty acids [19]. Cutaneous wounds in dogs fed
an n-3 enriched diet had reduced epithelialization and
contraction of open wounds and less edema in sutured
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assay in 3T3-Swiss fibroblasts (n = 3, ± SD)
In-vitro wounding assay in 3T3-Swiss fibroblasts (n =
3, ± SD). The addition treatment of L-NAME to LPS
increased the percentages of cellular recover area while the
treatment of L-NAME alone decreased it in wounded 3T3Swiss fibroblasts. When stimulated with LPS, EPA treated
fibroblasts had higher the percentage of cellular recover area
than the AA treated cells. Cells were incubated for 48 hr
with bovine serum albumin alone as control or bovine serum
albumin-soap loaded fatty acids (25 µM). Then wound was
created and the medium was replaced with fresh fatty acid
enriched medium containing lipopolysaccharide (LPS, 10 µg/
ml), NG-nitro-L-arginine methyl ester (L-NAME, 10-7 M) and
indomethacin (10-8 M) for another 24 hr. Multiple photographs of the wound were obtained and the percentage of
cellular recover areas were determined. Bars with different
letters are significantly different (P < 0.05). EPA, eicosapentaenoic acid; AA, arachidonic acid; LPS, lipopolysaccharide; LNAME, NG-nitro-L-arginine methyl ester; INDO,
indomethacin.

wounds after 5 days than dogs fed a diet enriched in n-6
fatty acids. However, the n-3 diet did not appear to have a
negative effect on wound healing [20]. A more recent
study found that topical application of oleic acid
(monounsaturated n-9 fatty acid) to surgically induced
skin wounds in mice resulted in more rapid wound closure than applications of linolenic acid (18:3, n-3) or linoleic acid (18:2, n-6) [18]. The topical application of
linolenic acid also resulted in an increased amount of connective tissue fibers compared to other fatty acid treatments. These limited studies suggest that in order to take
advantage of the inflammation mediating properties of
PUFA and use them as adjuvants in the healing process, it
may be necessary to use the different classes of PUFA

selectively during the stages of wound healing. Wound
healing consists of an inflammatory phase, a proliferative
(fibroblastic) phase, and a remodeling (maturation)
phase [21,22]. In addition, the type of wound (e.g., acute
or chouronic) and patient (e.g., diabetic, burn injured, or
immunosuppressed) will require matching the appropriate PUFA to the particular stage of wound healing. For
example, in immunosuppressed patients, a PUFA that
enhances inflammation in the early stages may be needed
to stimulate the healing process.
A component of optimal healing is regulation of collagen
formation. Favorable collagen formation includes both
enhanced collagen production for healing connective tissues and diminished formation in vital organs to minimize fibrosis. Our previous studies revealed that
polyunsaturated fatty acids affected a number of mediators and pathways involved in collagen formation [5,9].
Many collagen formation associated genes, such as IL-6
and iNOS, have promoter or enhancer elements for NF-κB
[23,24]. These genes provide ideal targets to connect various pathways involved in PUFA influenced collagen
formation. The present paper studied the link between
NF-κB pathway generated iNOS and nitric oxide (NO) in
PUFA altered collagen formation, and the association
with PGE2 production. Our hypothesis in the present
study is that polyunsaturated fatty acids can alter collagen
formation during in-vitro healing by changing iNOS
expression and NO production, which have cross-interaction with the NF-κB pathway and PGE2 (Figure 4, 5).
NO is synthesized from the terminal guanidine nitrogen
atom of L-arginine by nitric oxide synthase (NOS) and
involved in many biological functions [25]. The inducible
isoform of NOS (iNOS) is regulated primarily at the transcriptional level and contributes to most of the NO produced compared to the other isoforms [26]. The NF-κB
signaling pathway regulates promoter regions and
induces iNOS transcription [12]. In the present study
using real-time RT-PCR, activation of the NF-κB pathway
by LPS increased the transcription of iNOS mRNA in 3T3Swiss fibroblasts. The increase was greatest in EPA-treated
fibroblasts. Other researchers reported that NO can also
regulate iNOS transcription through a negative feedback
by inhibiting NF-κB binding to DNA [27]. In our experiments, the addition of a small amount of the nitric oxide
synthase inhibitor, L-NAME, increased the transcription
of iNOS mRNA only in EPA plus LPS treated normal
fibroblasts. However, the increased iNOS expression in
EPA plus LPS treated cells did not result in increased nitric
oxide (nitrite) production, and EPA plus LPS treated cells
produced less nitric oxide than control or AA treated cells.
The decreased amount of nitric oxide with EPA plus LPS
treatment may enhance iNOS expression due to decreased
negative feedback on NF-κB binding to DNA (Figure 4, 5).
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Figure 5 model for regulation of collagen formation in these experiments
Proposed
Proposed model for regulation of collagen formation in these experiments. 1. Activation of the nuclear factor-κB
(NF-κB) signaling pathway by lipopolysaccharide. 2. NO can inhibit the binding of NF-κB family members to target DNA. 3.
NF-κB family binding to DNA and transcription of iNOS mRNA. 4. L-NAME inhibits the production of NO from iNOS. 5. NO
regulates PGE2 production divergently through activation of COX isoforms. 6. Indomethacin inhibits COX and reduces
PGE2production. 7. Collagen production and wound healing processes are changed by the activation of different PGE2 receptors subtypes and second messengers. LPS, lipopolysaccharide; Tlr4, Toll-like receptor 4; Traf6, Tumor necrosis factor receptor-associated factor 6; IκB, Inhibitor of kappa light polypeptide gene enhancer in B-cell; NF-κB, nuclear transcription factor
kappaB; iNOS, inducible nitric oxide synthase; L-NAME, NG-nitro-L-arginine methyl ester; NO, nitric oxide; COX, cyclooxygenase; INDO, indomethacin; PKC, protein kinase C; cAMP, cyclic adenosine monophosphate.

The observation that increased iNOS expression in EPAtreated cells does not lead to increased NO production,
may be explained by altered post-transcriptional regulation that leads to reduced synthesis of iNOS protein and
thus decreased NO production.
Reduced NO in EPA treated cells, even though there is
increased transcription of iNOS mRNA, can also be linked
to PGE2 production in these cells. The amount of PGE2

produced by the 3T3 fibroblasts was inversely related to
the amount of nitric oxide produced. PGE2 will bind to
PGE receptors (EP1, EP2, EP3, and EP4) that activate signaling by protein kinase C (PKC) or cyclic AMP (cAMP).
Cells treated with AA are mainly responsive to signaling
from the EP1 receptor (PKC signaling), whereas EPAtreated cells are mainly responsive to EP2 and EP4 signaling (cAMP signaling) [5]. Arachidonic acid alone has been
shown to function as a secondary messenger and activate
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PKC. The increased amount of PGE2 in AA-treated cells
and stimulation of the PKC signaling pathway via the EP1
receptor (e.g., PKC activation) could affect post-translational synthesis of iNOS protein. Other studies identified
a role for PKC in the induction of iNOS by the NF-κB
pathway in murine 3T3 fibroblasts [28] and the nitric
oxide action on angiogenesis [29].
Nitric oxide regulates PGE2 production in a divergent
manner. Nitric oxide stimulated PGE2 release in macrophages [30,31] while endogenous NO inhibited PGE2
production in LPS-stimulated macrophages [32]. The dual
effect of NO on PGE2 production may be due to the
different effects on cyclooxygenase (COX) isoforms. Study
of COX isoform deficient murine fibroblasts revealed that
NO changed PGE2 production by activating COX-1 but
inhibiting COX-2 [30]. Other studies showed that low
concentrations of nitric oxide attenuate PGE2 production
induced by LPS, in part, due to decreased expression of
COX-2 protein [33]. However, LPS activation of the NFκB pathway can influence COX-2 gene expression by
directly altering COX-2 mRNA transcription [34]. Our
results showed that inhibition of NO with L-NAME,
decreased LPS-induced PGE2 production in normal 3T3Swiss fibroblasts. Thus, PGE2production in 3T3-Swiss
fibroblasts may be regulated at the COX-2 transcription
level through the NF-κB pathway or the COX-2 post-translational level through the production of NO derived via
nitric oxide synthase. The combination of PUFA treatment
(EPA) plus blocking of nitric oxide production with LNAME, resulted in a synergistic effect that enhanced collagen production compared to control fibroblasts.
The suppression of type I collagen gene expression by
PGE2 can be mediated by both altering the amount and
steady-state of collagen mRNA [35,36]. Interestingly, inhibition of iNOS activity has been shown to both slow collagen production in the healing process and also favor
collagen deposition and development of fibrosis [37]. It
was hypothesized that NO scavenged reactive oxygen
species by formation of peroxynitrite, and iNOS inhibition blocked NO formation and contributed to the development of fibrosis [37]. Therefore, appropriate induction
of iNOS from the NF-κB signaling pathway may be a critical mechanism for controlling collagen formation in
both fibrosis and proper wound healing.
Changes in collagen formation have also been correlated
to the concentration of NO produced. Collagen production (CP) and collagen as a percentage of total protein (CPTP) was increased in LPS and interferon-γ (IFN-γ) incubated wound derived murine fibroblasts [13]. Additional
treatments of NO synthase inhibitors decreased the CP
and C-PTP in the same study. However, LPS and IFN-γ
together, decreased, while inhibitors of NO restored the

http://www.lipidworld.com/content/4/1/14

collagen production in human small intestinal lamina
propria fibroblasts [38]. Another study in normal rat skin
fibroblasts showed that a nitric oxide donor at low concentration enhanced, but at higher concentration reverted
collagen synthesis back to control levels [4]. Dermal
fibroblasts from iNOS-knock out mice proliferated more
slowly and synthesized less collagen [15], and transfection with iNOS enhanced the collagen production in a
cutaneous wounded rat model [39]. In our experiments,
LPS stimulated the expression of iNOS mRNA, NO production, and collagen synthesis in 3T3-Swiss fibroblasts.
The additional incubation of small amount of L-NAME to
LPS decreased the NO production to a low level but
increased the expression of iNOS mRNA and the collagen
production.
Healing fibroblasts are phenotypically characterized by
changes in collagen production, cell proliferation, and
migration. Wound cells have been shown to increase the
expression of iNOS and production of NO in various
models [13,40]. Inhibition of iNOS delayed the reepithelialization in cutaneous wound repair [41]. The delayed
wound repair in iNOS knockout mice was reversed by
iNOS gene transfer [42]. Interestingly, the role of nitric
oxide on cell proliferation after wounding is
concentration-dependent [4]. At low concentration, NO
promoted cell proliferation in murine fibroblasts [43],
while at higher concentrations, NO decreased the proliferation of rat dermal skin fibroblasts [4]. The present study
showed that the treatment of L-NAME alone inhibited the
NO production and decreased the percentage of cellular
recoverage area in 3T3-Swiss fibroblasts. However, the
additional treatment of L-NAME to fibroblasts stimulated
by LPS increased cell proliferation and migration compared to the LPS treatments alone. L-NAME alone may
block the effect of nitric oxide at low concentration while
the addition of L-NAME plus LPS decreased the LPS
induced NO to a low concentration and increased the collagen formation, cell proliferation, and migration.
Indomethacin, a cyclooxygenase inhibitor, increased the
percentage of cellular recoverage area in fibroblasts with
LPS stimulation. The decreased PGE2 induced by
indomethacin also stimulated wound healing in 3T3Swiss fibroblasts.
In summary, we demonstrated that iNOS and NO provide
a cross-talk between the activation of the NF-κB pathway
and PGE2 in the PUFA altered fibroblast collagen production and wound healing. The use of PUFA for regulation
of collagen formation in wound healing or fibrosis will
require additional experiments in order to determine how
they may be used as adjuvants. Most likely it will be necessary to use a particular class of fatty acids (e.g., n-3, n-6,
n-9) appropriate to the type of wound and stage of wound
healing. In addition, use of fatty acids in combination
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with selective targeting of transcription factors and mediators (e.g., stimulation or inhibition) that regulate
collagen formation will provide the level of control necessary to adapt the treatment protocol to the type of wound.

Methods
Reagents
Reagents were purchased from Sigma-Aldrich, St. Louis,
MO, unless specified otherwise.
Cell culture and fatty acid enrichment
Mouse fibroblast (3T3-Swiss albino; American Type Culture Collection CCL-92, Rockville, MD) were maintained
as subconfluent monolayers in six-well plates (Corning
Costar, Cambridge MA) with Dulbecco's modified Eagle's
medium (DMEM), 4 mM L-glutamine, 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, and 10% bovine calf serum
(Hyclone, Logan, UT). Subconfluent cultures grown for
24 hr in maintenance medium were washed twice and
changed to fresh medium minus calf serum. In place of
serum, the control medium was supplemented with 5 mg/
100 ml of fatty acid free bovine serum albumin (BSA);
and the fatty acid enriched test media were supplemented
with BSA-loaded fatty acid soaps of arachidonic acid (AA,
20:4 n-6) or eicosapentaenoic acid (EPA, 20:5 n-3) (NuChek Prep, Elysian, MN) to a final concentration of 25
µM. Cells were grown for 48 hr in the test media prior to
addition of treatments described below.
In vitro wound assay
An in vitro wound healing assay was used to evaluate the
migration and proliferation of 3T3-Swiss fibroblast as previous studies [9]. Briefly, a sterile pipette tip was used to
make a 0.5-mm-wide wound by streaking across a
monolayer of 3T3 Swiss fibroblasts. The wound was created when the cells were about 80% confluent after the
initial 48 hr polyenoic fatty acid (PFA) enrichment and
the migration of fibroblasts into the wound was measured
at 24 hr post wounding. Multiple photographs of the
wound were obtained by phase contrast microscopy, and
the mean areas of cell recoverage for each sample were
determined with image analysis software (Optimas 6.1,
Media Cybernetics, Silver Spring, MD). The percentage of
cellular recoverage area to the whole wound area was
measured to evaluate the combined effects of cell proliferation and migration.

A similar set of plates was used to perform the real-time
RT-PCR of iNOS, quantification of nitrite and PGE2, and
collagen synthesis. For real-time RT-PCR and the quantification of nitrite and PGE2, the following protocol was
used. After the initial 48 hr PFA enrichment, the media
was changed with fresh fatty acid enriched medium containing Eshericia coli O55:B5 lipopolysaccharide (LPS, 10
µg/ml) with or without NG-nitro-L-arginine methyl ester
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(L-NAME, 10-7 M) and indomethacin (INDO, 10-8 M).
Lipopolysaccharide is used to activate the NF-κB pathway
and mimic some aspects of in vivo inflammation. For collagen formation, after the initial 48 hr polyenoic fatty acid
(PFA) enrichment, the media was replaced with fresh fatty
acid enriched medium containing 50 µM ascorbic acid
and 5 µCi of 3H-proline (Amersham, Arlington Heights
IL) with or without treatments. At 24 hr post wounding, a
portion of the media was collected or the cells were harvested. Parallel plates were also cultured with the same
treatments but without wounding. The cells for all treatments used in these experiments had greater than 99%
viability based upon the standard trypan blue dye exclusion test.
RNA isolation and cDNA synthesis
After cells were washed with Hank's balanced salt solution
and harvested, total RNA was isolated using a commercially available kit (RNAqueous, Ambion, Austin, TX) and
digested with RNase-free DNase, as recommended by the
supplier. The concentration and purity of total RNA were
determined by measuring the optical density at 260 and
280 nm. The ratio of absorbance at 260 to 280 nm was
1.8–2.0. Two µg total RNA was reverse transcribed using a
cDNA synthesis Kit (iScript™ cDNA Synthesis Kit, Bio-Rad
Laboratories, Hercules, CA) following the manufacture's
instructions. Generated cDNA were diluted with RNA-free
water before usage.
Real-time RT-PCR
Synthesized cDNA encoding for murine iNOS and β-actin
(as endogenous control) were amplified and analyzed by
a real-time reverse transcription polymerase chain reaction (real time RT-PCR) system (Applied Biosystems 7300
Real Time PCR System, Foster City, CA). The oligonucleotide primers were designed by Primer Express software
(Primer Express 2.0, Applied Biosystems) and ordered
from IDT (Integrated DNA Technologies, Coralville, IA).
The cDNA sequences were obtained from the Genebank
database as indicated in table 1. PCR amplifications were
performed according to the manufacture's protocol. Samples were prepared in a total volume of 50 µl containing 2
µl cDNA sample (diluted 1x, 10x, 100x, 200x), 25 µl SYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
CA), 1 µl each primer, and 21 µl RNA-free water. For each
reaction, the polymerase was initiated at 50°C for 2 min
and 95°C for 10 min, and amplification was then performed at 35 cycles of switching between 95°C for 15 seconds, 55°C for 30 seconds, and 72°C for 15 seconds
followed by melting point analysis from 60°C to 95°C.
All samples were done in triplicate and the coefficient was
determined by creating a standard curve from plotting CT
values vs. the total RNA. The results were presented as the
mRNA expression percentage of iNOS to β-actin.
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Quantification of nitrite
Nitrite (NO2-) in culture supernatants was measured to
determine the synthesis of NO as other studies [17]. Culture supernatants (100 µl) were mixed with an equal volume of Griess reagent (1% sulfanilamide, 0.1%
naphthylethylene diamine dihydrochloride and 2.5%
phosphoric acid) and incubated at the room temperature
with dimmed light for 10 min. Nitrite was measured at
550 nm by a microplate reader (EIA reader 2550, Bio-Rad,
Hercules, CA) using the double-distilled water as blank
and the sodium nitrite to generate a standard curve.
Quantification of PGE2
Assessment of total prostaglandin E2 (PGE2) amount from
the medium of 3T3-Swiss fibroblasts incubation was
preformed by an ELISA kit (Monoclonal prostaglandin E2
EIA Kit-514010; Cayman Chemical, Ann Arbor, MI),
according to the manufacturer's recommended protocol.
Collagen assay
Collagen was assayed as described previously [5]. The
media was collected and the cells washed twice with cold
phosphate buffered saline (PBS). The cells were pelleted
by centrifugation and the PBS wash combined with the
media fraction. The cell pellet was suspended in 1.0 ml of
ammonium hydroxide-Triton X-100 cell lysing solution
(AT solution). Following 15-minute incubation at 37°C,
750 µl of the lysate is combined with the media fraction.
The two fractions, cell and media, then underwent trichloroaceticic acid (TCA) precipitation (equal volume of 20%
TCA added to the cell plus media fraction). The acid insoluble precipitate was then rinsed several times with 10%
TCA to remove free 3H-proline. The precipitate was redissolved in 0.05 N NaOH in 0.05 M TES buffer plus 0.005
M CaCl2 and half of the solution incubated for 6 hr at
37°C with protease-free Type VII collagenase (100 U/ mL)
in TES and the other half of the solution served as a control. Following the digestion, TCA was again added to precipitate the acid insoluble proteins; however, the collagen
fragments generated by collagenase treatment remain in
solution. The supernatant and precipitate were counted in
a scintillation counter and collagen, non-collagenous,
and total protein production reported as DPM/µg DNA.
DNA assay
The remaining 250 µl of the AT solution cellular-lysate
from the collagen synthesis assay was used for total DNA
determination. Picogreen, 50 µl (Molecular Probes,
Eugene OR) was added to 50 µl of lysate or to 50 µl of
known DNA standards and fluorescence of the dye binding to double stranded DNA was measured in a
spectofluorometer. A DNA standard curve was generated
by linear regression and sample DNA values was used to
obtain the unknown values.
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Statistical analysis
Data were presented as means ± standard deviation (SD)
and analyzed by both one-way and two-way ANOVA
procedures of SAS (SAS Institute, Cary, NC). A Tukey test
was used to analyze significant main and interaction
effects. A P value < 0.05 was considered statistically
significant.
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